CN110824079B

CN110824079B - Purification method of telavancin

Info

Publication number: CN110824079B
Application number: CN201911180481.8A
Authority: CN
Inventors: 贺元康; 王艺
Original assignee: Sepax Technologies Suzhou Co ltd
Current assignee: Suzhou saifen Technology Co.,Ltd.
Priority date: 2019-11-27
Filing date: 2019-11-27
Publication date: 2021-04-13
Anticipated expiration: 2039-11-27
Also published as: CN110824079A

Abstract

The invention relates to a purification method of telavancin. The method comprises the following steps: adding the crude telavancin into a solvent, fully dissolving, filtering and retaining filtrate to obtain a sample solution; loading the sample loading liquid to a separation column filled with a filler to separate a target component and an impurity component in the sample loading liquid, wherein the target component is remained in the filler after the sample loading; eluting the target component in the filler by using an eluent to obtain a target effluent liquid, wherein the eluent is a mixed liquid of an organic solvent and water or the organic solvent; and collecting the target effluent to obtain the purified telavancin. The purification method of telavancin does not need steps of extraction, column chromatography, crystallization and the like, has simple process and lower production cost, and is integrally beneficial to application. Tests prove that the purity of the purified telavancin product obtained by the purifying method of telavancin is more than 99%, the single impurity content is less than 0.5%, the period is short, and the method has good feasibility and practicability and is suitable for industrial production.

Description

Purification method of telavancin

Technical Field

The invention relates to the field of medicines, in particular to a method for purifying telavancin.

Background

Telavancin (Telavancin) is a novel lipoglycopeptide antibiotic developed by schwann (Theravance) and Astellas (Astellas) pharmaceutical, japan. The chemical name is N-3' -2- (decylamino) ethyl-29- [ (N-phosphonomethyl) aminomethyl ] vancomycin hydrochloride. Marketed in the united states in 2009, it was indicated for adult complex skin infections caused by gram-positive bacteria. The european union has increased usage in 2011 for the treatment of adult hospital-acquired pneumonia and ventilator-associated pneumonia that have been diagnosed or suspected to be caused by methicillin-resistant staphylococcus aureus (MRSA). Telavancin is the second generation of semi-synthetic lipoglycopeptide antibiotics, and the parent drug core of telavancin is vancomycin. Compared with vancomycin, telavancin is formed by connecting a hydrophobic group, namely decylaminoethyl, to vancomycin sugar amine, so that the affinity of the vancomycin sugar amine to a bacterial cell membrane is favorably increased, the membrane anchoring is favorably realized, the half-life period is prolonged, and the antibacterial activity to enterococcus is improved; and the acyl position of the 7 th amino acid is connected with the amino phosphate, so that the water solubility is increased, the metabolism and the clearance of tissues in vivo are promoted, the renal toxicity is reduced, and the pharmacokinetic property of the medicament in vivo is improved. As a novel lipoglycopeptide antibiotic, the unique action mechanism and good clinical treatment effect of telavancin can be expected to have wide market prospect.

Telavancin is not pure enough and further purification is required. However, the conventional purification method of telavancin is complicated, requires extraction, column chromatography, crystallization and other steps, is time-consuming, leads to high cost, is difficult to industrially amplify and produce, and is not beneficial to application.

Disclosure of Invention

Therefore, it is necessary to provide a purification method of telavancin with simple process and high purity for the problem of complicated purification steps of telavancin.

A method for purifying telavancin, comprising the following steps:

adding the crude telavancin into a solvent, fully dissolving, filtering and retaining filtrate to obtain a sample solution;

loading the sample loading liquid to a separation column filled with a filler to separate a target component and an impurity component in the sample loading liquid, wherein the target component is remained in the filler after the sample loading;

eluting the target component in the filler by adopting an eluent to obtain a target effluent, wherein the eluent is a mixed solution of an organic solvent and water or an organic solvent; and collecting the target effluent to obtain the purified telavancin.

Compared with the traditional purification method of telavancin, the purification method of telavancin only needs to load the sample loading solution to a separation column, then elute and reserve the target effluent, and collect to obtain the purified telavancin. Without the steps of extraction, column chromatography, crystallization and the like. Therefore, the purification method of telavancin has the advantages of simple process, low production cost and overall benefit for application. In addition, tests prove that the purity of the purified telavancin product obtained by the purification method of telavancin is more than 99%, the single impurity content is less than 0.5%, the period is short, and the method has good feasibility and practicability and is very suitable for industrial production.

In one embodiment, the crude telavancin is added into a solvent, wherein the solvent is one or more of a methanol aqueous solution containing 0.05-0.5% by volume of organic acid and an acetonitrile aqueous solution containing 0.05-0.5% by volume of organic acid; wherein the organic acid is one or more of trifluoroacetic acid, formic acid and acetic acid; the volume fraction of methanol or acetonitrile in the solvent is 20-50 percent respectively.

In one embodiment, the filler is silica gel as a matrix, and decaoctasilane and divinylbenzene are bonded on the silica gel, wherein the mass ratio of octadecylsilane to divinylbenzene is (1-6): 1.

In one embodiment, the filler has a particle size of 10 to 50 μm and a pore size of

In one embodiment, in the operation of loading the loading solution to the separation column filled with the filler, the mass ratio of the solute in the loading solution to the filler is 1: 100-11: 100.

In one embodiment, the step of loading the loading solution to the separation column filled with the filler further comprises the following steps: the separation column filled with the packing is equilibrated with an eluent.

In one embodiment, the eluent is one or more of methanol aqueous solution containing 0.05-0.5% of organic acid volume fraction and acetonitrile aqueous solution containing 0.05-0.5% of organic acid volume fraction; wherein the organic acid is one or more of trifluoroacetic acid, formic acid and acetic acid; the volume fraction of methanol or acetonitrile in the solvent is 20-50 percent respectively.

In one embodiment, the target component is eluted by an eluent at a flow rate of 100cm/h to 500 cm/h.

In one embodiment, the step of collecting the target effluent in stages further comprises the steps of: and detecting the target effluent, and freeze-drying the qualified sample after detection.

In one embodiment, the crude telavancin is 70% to 90% pure.

Drawings

FIG. 1 is a flow diagram of a process for purifying telavancin in accordance with one embodiment of the present invention;

FIG. 2 is a high performance liquid chromatogram of example 1 of the present invention after purification of crude Telavancin.

Detailed Description

In order to make the aforementioned objects, features and advantages of the present invention comprehensible, embodiments accompanied with figures are described in detail below. In the following description, numerous specific details are set forth in order to provide a thorough understanding of the present invention. This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. As used herein, the term "and/or" includes any and all combinations of one or more of the associated listed items.

Referring to fig. 1, the method for purifying telavancin according to an embodiment of the present invention includes the following steps:

s10, adding the crude telavancin into the solvent, fully dissolving, filtering and retaining the filtrate to obtain a sample solution.

Preferably, the purity of the crude telavancin is 70% to 90%. That is to say, the purification method of telavancin can be applied to crude telavancin products with the purity of 70% -90%, and tests prove that the purification effect is good.

Preferably, in the operation of adding the crude telavancin into the solvent, the solvent is one or more of methanol aqueous solution containing 0.05-0.5% of organic acid by volume fraction and acetonitrile aqueous solution containing 0.05-0.5% of organic acid by volume fraction; wherein the organic acid is one or more of trifluoroacetic acid, formic acid and acetic acid; the volume fraction of methanol or acetonitrile in the solvent is 20-50 percent respectively. The solvents are easy to obtain, have low cost, can not react with telavancin or generate adverse effects, and are easy to remove subsequently.

And S20, loading the sample loading liquid obtained in the step S10 to a separation column filled with the filler, so as to separate the target component and the impurity component in the sample loading liquid, wherein the target component is remained in the filler after loading.

Wherein the separation column is a preparative liquid chromatography column. The filler is special for telavancin.

Preferably, the filler is silica gel as a matrix, and decaoctasilane and divinylbenzene are bonded on the silica gel, wherein the mass ratio of the octadecylsilane to the divinylbenzene is (1-6): 1.

More preferably, the filler has a particle size of 10 to 50 μm and a pore size of

Preferably, in the operation of loading the loading liquid to the separation column filled with the filler, the mass ratio of the solute in the loading liquid to the filler is 1: 100-11: 100.

Preferably, the step of loading the loading liquid to the separation column filled with the filler further comprises the following steps: and (4) balancing the separation column filled with the filler by using eluent, and starting to sample after the base line is leveled.

And S30, eluting the target component in the filler obtained in the step S20 by using an eluent to obtain a target effluent, wherein the eluent is a mixed solution of an organic solvent and water or the organic solvent.

Preferably, the eluent is one or more of methanol aqueous solution containing 0.05-0.5% of organic acid volume fraction and acetonitrile aqueous solution containing 0.05-0.5% of organic acid volume fraction; wherein the organic acid is one or more of trifluoroacetic acid, formic acid and acetic acid; the volume fraction of methanol or acetonitrile in the solvent is 20-50 percent respectively. These types of eluents are readily available, low cost, do not react with telavancin or otherwise adversely affect, and are subsequently easily removable.

Preferably, in the operation of eluting the target component by adopting the eluent, the flow rate of the eluent is 100 cm/h-500 cm/h; more preferably, the flow rate of the eluent is 200 cm/h-400 cm/h; most preferably, the elution flow rate is 300 cm/h.

S40, collecting the target effluent obtained in the step S30 to obtain the purified telavancin.

Preferably, the step of collecting the target effluent in stages further comprises the following steps: detecting the target effluent liquid, and freeze-drying the qualified sample after detection.

The purification process of telavancin according to the present invention will be further described with reference to specific examples and comparative examples.

The separation columns used in examples 1-8 were: the preparation method of the telavancin comprises the steps of preparing a column (100mm x 250 mm; the used filler is silica gel which is used as a substrate, and bonding octadecane silane and divinylbenzene on the silica gel, wherein the mass ratio of the octadecane silane to the divinylbenzene is (1-6): 1.

Example 1

1. Weighing a sample: weighing 40g of crude telavancin on an analytical balance;

2. preparing a solvent: 400ml of 30 vol% methanol aqueous solution containing 0.1 vol% formic acid was prepared by the following steps: taking 120ml of methanol, 380ml of purified water, taking 400ul of formic acid by a liquid transfer gun, mixing the three, stirring uniformly, and preparing two parts for later use;

3. sample dissolution: adding one part of the solvent prepared in the step 2 into 40g of crude telavancin in the step 1, sealing the mixture by using a preservative film, adding a stirrer, and keeping the stirring state on a magnetic stirrer to fully dissolve the solvent;

4. and (3) chromatographic column balancing: on an LC6000 instrument, a channel A is 0.1% formic acid aqueous solution, a channel B is methanol (containing 0.1% formic acid), under the condition of connecting a telavancin preparation column, the flow rate is 400ml/min (converted from 300cm/h linear flow rate), the column is balanced by 70% A (280ml/min) and 30% B (120ml/min), and the balance time is 15 min;

5. sample loading: stopping all pumps after the step 4 is finished, inserting the pipeline A into the other part of the prepared solvent, flushing the pipeline A at the speed of 400ml/min, and stopping the pumps after 0.5 min; changing the pipeline A into the prepared crude telavancin product, loading the sample at the speed of 400ml/min for 1min, stopping the pump, changing into the solvent left in the step 2, flushing at the speed of 400ml/min for 0.5min, and stopping the pump;

6. sample elution: after step 5 was completed, pump A was changed to pure water while on-line signal recording from the preparation workstation was started and the column was rinsed with 30% B (120ml/min) at 400 ml/min;

7. collecting samples: when the target peak appears, the sample is collected for 3min, and the samples are received for 10 times; as shown in fig. 2, collecting the components with retention time of 36 min-66 min;

8. collecting samples for analysis: the sample was collected on analytical column GP-C18 (particle size 5 μm, pore size: GP-C18)

) The above analysis;

9. analyzing and combining samples: sampling, detecting by HPLC (high performance liquid chromatography), collecting all qualified components, mixing, and vacuum freezing and lyophilizing. The purified sample was 30.48g, the purity was 99.17%, the single impurity was less than 0.5%, and the recovery was 76.20%.

Example 2

Taking 40g of crude telavancin with the content of 80.09% (m/m), adding 400ml of 25% acetonitrile (V/V) containing 0.1% trifluoroacetic acid, and stirring to fully dissolve. The sample was applied to a telavancin preparative column equilibrated with 25% acetonitrile containing 0.1% trifluoroacetic acid at a flow rate of 200 ml/min. After loading, the column was eluted with 25% acetonitrile containing 0.1% trifluoroacetic acid at a flow rate of 400ml/min for a total of 100 min. And (4) collecting component solutions of telavancin by HPLC detection, combining qualified components, and freeze-drying to obtain 30.87g of a pure telavancin product. Purity was 99.22% by HPLC, single impurity was less than 0.5%, recovery was 77.18%.

Example 3

Taking 40g of crude telavancin with the content of 80.09% (m/m), adding 400ml of 25% acetonitrile (V/V) of 0.1% formic acid, and stirring to fully dissolve. The sample was loaded onto a teracin preparative column equilibrated with 25% acetonitrile in 0.1% formic acid at a flow rate of 200 ml/min. After loading, the mixture is eluted by 25 percent acetonitrile with the flow rate of 400ml/min for 100 min. And (4) collecting component solutions of telavancin by HPLC detection, combining qualified components, and freeze-drying to obtain 31.27g of a pure telavancin product. The purity of the product is 99.09% by HPLC detection, the single impurity content is less than 0.5%, and the recovery rate is 78.18%.

Example 4

Taking 40g of crude telavancin with the content of 80.09% (m/m), adding 400ml of 30% methanol (V/V) with 0.1% trifluoroacetic acid, and stirring to fully dissolve. The sample was applied to a teracin preparation column equilibrated with 30% methanol containing 0.1% trifluoroacetic acid at a flow rate of 200 ml/min. After loading, the column was eluted with 30% methanol (containing 0.1% trifluoroacetic acid) at a flow rate of 400ml/min for a total of 100 min. And (4) collecting component solutions of telavancin by HPLC detection, combining qualified components, and freeze-drying to obtain 31.51g of a pure telavancin product. The purity of the product is 99.15% by HPLC detection, the single impurity content is less than 0.5%, and the recovery rate is 78.78%.

Example 5

Taking 78.1g (11% of the filler weight) of crude telavancin with the content of 85.25% (m/m), adding 400ml of 30% methanol (V/V) of 0.1% formic acid, and stirring to fully dissolve. The sample was applied to a teracin preparation column equilibrated with 30% methanol containing 0.1% formic acid at a flow rate of 200 ml/min. After loading, the column was eluted with 30% methanol (containing 0.1% formic acid) at a flow rate of 400ml/min for a total of 100 min. And (4) collecting component solutions of telavancin by HPLC detection, combining qualified components, and freeze-drying to obtain 53.81g of a pure telavancin product. Purity by HPLC was 99.19%, single impurity was less than 0.5%, recovery was 75.79%.

Example 6

78.1g of crude telavancin (11% of the filler weight) with a content of 80.09% (m/m) was taken, 400ml of 30% methanol (V/V) with 0.1% formic acid was added, and the mixture was stirred to be sufficiently dissolved. The sample was applied to a teracin preparation column equilibrated with 30% methanol containing 0.1% formic acid at a flow rate of 200 ml/min. After loading, the column was eluted with 30% methanol (containing 0.1% formic acid) at a flow rate of 400ml/min for a total of 100 min. And (4) collecting component solutions of telavancin by HPLC detection, combining qualified components, and freeze-drying to obtain 24.35g of a pure telavancin product. Purity was 99.03% by HPLC, single impurity was less than 0.5%, recovery was 31.18%.

Example 7

Taking 40g of crude telavancin with the content of 80.09% (m/m), adding 400ml of 55% methanol (V/V) with 0.1% formic acid, and stirring to fully dissolve. The sample was applied to a teracin preparative column equilibrated with 55% methanol containing 0.1% formic acid at a flow rate of 200 ml/min. After loading, the column was eluted with 55% methanol (containing 0.1% formic acid) at a flow rate of 400ml/min for a total of 100 min. And (4) collecting component solutions of telavancin by HPLC detection, combining qualified components, and freeze-drying to obtain 13.57g of a pure telavancin product. The purity of the product is 99.08 percent by HPLC detection, the single impurity is less than 0.5 percent, and the recovery rate is 33.93 percent.

Example 8

Taking 40g of crude telavancin with the content of 80.09% (m/m), adding 400ml of 55% acetonitrile (V/V) of 0.1% trifluoroacetic acid, and stirring to fully dissolve. The sample was applied to a teracin preparation column equilibrated with 55% acetonitrile containing 0.1% trifluoroacetic acid at a flow rate of 200 ml/min. After loading, the column was eluted with 55% acetonitrile (containing 0.1% trifluoroacetic acid) at a flow rate of 400ml/min for 100 min. And (4) collecting component solutions of telavancin by HPLC detection, combining qualified components, and freeze-drying to obtain 12.96g of a pure telavancin product. The purity of the product is 99.12% by HPLC detection, the single impurity content is less than 0.5%, and the recovery rate is 32.40%.

Comparative example 1

40g of crude telavancin with the content of 80.09% (m/m) is taken, 240ml of methanol-formic acid-water solution (the volume ratio is 2: 1: 1) is added, the mixture is stirred uniformly and then filtered, and the filtrate is purified by a chromatographic column. The chromatography medium was naphthyl-bonded silica gel, 2600g in weight, eluted at 2BV/h with 20% ethanol pH 2.4 containing 0.04mol/L ammonium dihydrogen phosphate. Collecting the components with purity of more than 95%, concentrating, adding hydrochloric acid aqueous solution with pH of 4.0 during concentration to remove buffer salt, and concentrating to 1/10. Heating the concentrated solution to 45 ℃, adding 7 times of ethanol, uniformly stirring, then adding 0.9 times of diethyl ether, stirring, cooling to 5 ℃, filtering, and washing with an ethanol-diethyl ether-water solution (volume ratio is 4: 2: 1) for a plurality of times to obtain 20.12g of a pure telavancin product. The purity of the obtained pure telavancin product is detected to be 98.83%, and the yield is 50.30%.

The purified telavancin of example 1 was compared to the purified telavancin of comparative example 1, and the data for the ratio is shown in table 1:

TABLE 1

	Liquid phase purity (%)	Recovery (%)	Time consuming
				Example 1	99.17	76.20	2h
Comparative example 1	98.83	50.30	6h

As can be seen from table 1:

(1) the liquid phase purity of the purified telavancin product obtained by the purification method of telavancin in embodiment 1 of the invention is as high as 99.17%, which is 0.34% higher than that of the purified telavancin product in comparison with the comparative example 1, which shows that the purification method of telavancin in embodiment 1 of the invention can obtain higher purity telavancin;

(2) the recovery rate of the purified telavancin obtained by the purification method of telavancin in embodiment 1 of the invention is as high as 76.20%, which is 25.90% higher than that of the purified telavancin in comparison with that of comparative example 1, and shows that the recovery rate of the purification method of telavancin in embodiment 1 of the invention is higher;

(3) the purification method of telavancin in example 1 of the present invention takes only 2 hours, which is one third of the purification method of the pure telavancin in comparative example 1, indicating that the purification method of telavancin in example 1 of the present invention takes less time.

In addition, by comparing examples 1 to 8 of the present invention with comparative example 1, the following conclusions can be obtained:

(1) tests prove that the purity of the telavancin obtained by the purification method of the telavancin in the embodiments 1-8 is more than 99%;

(2) tests prove that the recovery rate of the telavancin obtained by the purification method of the telavancin in the embodiments 1-5 is more than 75%;

(3) comparing example 5 with example 6, it can be seen that: when the mass ratio of the solute to the filler in the sample solution exceeds 11:100, the purification effect (yield) may be reduced, and therefore the amount of the purified sample is preferably 1:100 to 11: 100.

(4) Comparing examples 1-4 with examples 7 and 8, it can be seen that: when the volume fraction of the solvent and the effective components in the eluent is 20-50%, the recovery rate of the obtained pure Telavancin product is high.

The technical features of the embodiments described above may be arbitrarily combined, and for the sake of brevity, all possible combinations of the technical features in the embodiments described above are not described, but should be considered as being within the scope of the present specification as long as there is no contradiction between the combinations of the technical features.

The above-mentioned embodiments only express several embodiments of the present invention, and the description thereof is more specific and detailed, but not construed as limiting the scope of the invention. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention. Therefore, the protection scope of the present patent shall be subject to the appended claims.

Claims

1. A method for purifying telavancin is characterized by comprising the following steps:

eluting the target component in the filler by adopting an eluent to obtain a target effluent, wherein the eluent is a mixed solution of an organic solvent and water or an organic solvent; and

collecting the target effluent to obtain purified telavancin;

the filler takes silica gel as a substrate, and octadodecyl silane and divinyl benzene are bonded on the silica gel, wherein the mass ratio of octadecyl silane to divinyl benzene is (1-6): 1;

the particle size of the filler is 10-50 μm;

the eluent is one or more of methanol aqueous solution containing 0.05 to 0.5 volume percent of organic acid and acetonitrile aqueous solution containing 0.05 to 0.5 volume percent of organic acid; wherein the organic acid is one or more of trifluoroacetic acid, formic acid and acetic acid.

2. The method for purifying telavancin according to claim 1, wherein the crude telavancin is added to a solvent, wherein the solvent is one or more of an aqueous methanol solution containing 0.05-0.5% by volume of organic acid and an aqueous acetonitrile solution containing 0.05-0.5% by volume of organic acid; wherein the organic acid is one or more of trifluoroacetic acid, formic acid and acetic acid.

3. A process for the purification of telavancin according to claim 2, wherein the volume fraction of methanol or acetonitrile in the solvent is from 20% to 50%, respectively.

4. A process for the purification of telavancin as claimed in claim 1, wherein said packing has a pore size of

5. The method for purifying telavancin according to claim 1, wherein a mass ratio of the solute in the sample liquid to the filler is 1:100 to 11:100 in an operation of loading the sample liquid into a separation column filled with the filler.

6. The method of purifying telavancin according to claim 1, further comprising, prior to the step of loading the loading solution onto a packed separation column: the separation column filled with the packing is equilibrated with an eluent.

7. A process for the purification of telavancin according to claim 1 or 6, wherein the volume fraction of methanol or acetonitrile in the eluent is 20% to 50%, respectively.

8. The method of claim 1, wherein the elution of the target component with an eluent is carried out at a flow rate of 100cm/h to 500 cm/h.

9. The method of purifying telavancin according to claim 1, further comprising, after the step of collecting the target effluent, the steps of: and detecting the target effluent, and freeze-drying the qualified sample after detection.

10. The method for purifying telavancin according to claim 1, wherein the purity of the crude telavancin is 70% to 90%.